November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
October 2025 in “Animals” Blue light masks improved coat condition and energy in horses with PPID.
August 2025 in “Aesthetic Plastic Surgery” Collaboration and innovation are key to developing effective, safe hair loss treatments.
July 2025 in “Preprints.org” Specific miRNA profiles can help diagnose and treat alopecia areata.
June 2025 in “Clinical Cosmetic and Investigational Dermatology” Gray hair can potentially be managed or reversed with treatments that boost melanin production and address nutritional deficiencies.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.
May 2025 in “American Journal of Veterinary Research” Photobiomodulation did not significantly improve hair density in dogs with alopecia X.
May 2025 in “Journal of Inflammation Research” Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.
February 2025 in “Healthcare” Caffeine may help with hair loss, but more research is needed.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
December 2024 in “Pakistan Armed Forces Medical Journal” PRP is more effective than Minoxidil for treating alopecia areata.
August 2024 in “Frontiers in Public Health” Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
May 2024 in “Frontiers in Nutrition” Turning food waste into useful products is key for a sustainable economy.
Combining PRP with Tressfix Serum is more effective for hair regrowth in telogen effluvium than using either alone.
April 2024 in “MGM Journal of Medical Sciences” Traditional Indian home remedies are effective and culturally important.
February 2024 in “The Open dermatology journal” Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
Hair proteins in preschool children and their mothers could indicate developmental changes and health status.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
December 2022 in “Dermatology and Therapy” Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
December 2022 in “IntechOpen eBooks” 308 excimer phototherapy is a safe and effective way to treat hair loss from Alopecia Areata.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
14 citations
,
August 2018 in “Journal of Pharmaceutical and Biomedical Analysis”
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly medicines targeting harmful microbes, free for personal use.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly antimicrobials free for everyone.